Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 6/20 | 0.60 |
| ▸ | RAB9A | P51151 | 6/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.60 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.60 |
| ▸ | EIF4E | P06730 | 10/20 | 0.58 |
| ▸ | MEN1 | O00255 | 6/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.55 |
| ▸ | MAPT | P10636 | 2/20 | 0.52 |
| ▸ | TP53 | P04637 | 1/20 | 0.52 |
| ▸ | HTT | P42858 | 1/20 | 0.52 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.50 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1505261 | 0.96 | KDM4E (0.62) | NPC1RAB9ASMN1; SMN2KDM4EEIF4E | |
| SCHEMBL16716680 | 0.88 | KDM4E (0.60) | NPC1RAB9ASMN1; SMN2KDM4EEIF4E | |
| SCHEMBL12171986 | 0.86 | KDM4E (0.64) | NPC1RAB9ASMN1; SMN2KDM4EEIF4E | |
| SCHEMBL1505287 | 0.86 | SREBF2 (0.65) | NPC1RAB9ASMN1; SMN2KDM4EEIF4E | |
| SCHEMBL7215552 | 0.86 | KDM4E (0.73) | NPC1RAB9ASMN1; SMN2KDM4EEIF4E | |
| SCHEMBL7217156 | 0.86 | KDM4E (0.72) | NPC1RAB9ASMN1; SMN2KDM4EEIF4E | |
| SCHEMBL28075899 | 0.85 | KDM4E (0.79) | NPC1RAB9AKDM4EEIF4EMEN1 | |
| SCHEMBL12871690 | 0.84 | EIF4E (0.64) | NPC1RAB9ASMN1; SMN2KDM4EEIF4E | |
| SCHEMBL1505172 | 0.84 | L3MBTL1 (0.54) | NPC1RAB9ASMN1; SMN2KDM4EEIF4E | |
| SCHEMBL17336823 | 0.84 | KDM4E (0.64) | NPC1RAB9ASMN1; SMN2KDM4EEIF4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6545009-B1 | Imidazole, oxazole and thiazole derivatives for regulation of peroxisome proliferator-activated receptor function; improving insulin resistance, treating impaired glucose tolerance and obesity, enhancing insulin sensitivity, etc. | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2003-04-08 | — | — | US | claimed |
| CN-1314899-A | Retinoid-associated receptor regulators | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 2001-09-26 | — | — | CN | claimed |
| EP-1092711-A1 | RETINOID-ASSOCIATED RECEPTOR REGULATORS | Takeda Chemical Industries, Ltd. (JP) | 2001-04-18 | — | — | EP | claimed |
| US-20170204073-A1 | COMPOUNDS FOR NONSENSE SUPPRESSION, AND METHODS FOR THEIR USE | PTC THERAPEUTICS, INC. (US) | 2017-07-20 | — | — | US | disclosed |
| US-20170204073-A1 | COMPOUNDS FOR NONSENSE SUPPRESSION, AND METHODS FOR THEIR USE | PTC THERAPEUTICS, INC. (US) | 2017-07-20 | — | — | US | disclosed |
| US-20170204073-A1 | COMPOUNDS FOR NONSENSE SUPPRESSION, AND METHODS FOR THEIR USE | PTC THERAPEUTICS, INC. (US) | 2017-07-20 | — | — | US | disclosed |
| US-9611230-B2 | 1,3,4-oxadiazole benzoic acid compounds and their use for nonsense suppression and the treatment of disease | PTC THERAPEUTICS, INC. (US) | 2017-04-04 | — | — | US | disclosed |
| US-9611230-B2 | 1,3,4-oxadiazole benzoic acid compounds and their use for nonsense suppression and the treatment of disease | PTC THERAPEUTICS, INC. (US) | 2017-04-04 | — | — | US | disclosed |
| US-9611230-B2 | 1,3,4-oxadiazole benzoic acid compounds and their use for nonsense suppression and the treatment of disease | PTC THERAPEUTICS, INC. (US) | 2017-04-04 | — | — | US | disclosed |
| EP-3067053-A1 | COMPOUNDS FOR NONSENSE SUPPRESSION, AND METHODS FOR THEIR USE | PTC Therapeutics, Inc. (US) | 2016-09-14 | — | — | EP | disclosed |
| EP-3067053-A1 | COMPOUNDS FOR NONSENSE SUPPRESSION, AND METHODS FOR THEIR USE | PTC Therapeutics, Inc. (US) | 2016-09-14 | — | — | EP | disclosed |
| US-20090253699-A1 | Compounds for Nonsense Suppression, and Methods for Their Use | PCT THERAPEUTICS, INC. (US) | 2009-10-08 | — | — | US | disclosed |
| US-20090253699-A1 | Compounds for Nonsense Suppression, and Methods for Their Use | PCT THERAPEUTICS, INC. (US) | 2009-10-08 | — | — | US | disclosed |
| CN-101076703-A | Compounds for nonsense inhibition and methods of use thereof | PTC THERAPEUTICS INC (US) | 2007-11-21 | — | — | CN | disclosed |
| WO-2007117438-A2 | METHODS FOR THE PRODUCTION OF FUNCTIONAL PROTEIN FROM DNA HAVING A NONSENSE MUTATION AND THE TREATMENT OF DISORDERS ASSOCIATED THEREWITH | PTC THERAPEUTICS, INC. (US) | 2007-10-18 | — | — | WO | disclosed |
| EP-1815206-A1 | COMPOUNDS FOR NONSENSE SUPPRESSION, AND METHODS FOR THEIR USE | PTC Therapeutics, Inc. (US) | 2007-08-08 | — | — | EP | disclosed |
| WO-2006044456-A1 | COMPOUNDS FOR NONSENSE SUPPRESSION, AND METHODS FOR THEIR USE | PTC THERAPEUTICS, INC. (US) | 2006-04-27 | — | — | WO | disclosed |
| US-6545009-B1 | Imidazole, oxazole and thiazole derivatives for regulation of peroxisome proliferator-activated receptor function; improving insulin resistance, treating impaired glucose tolerance and obesity, enhancing insulin sensitivity, etc. | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2003-04-08 | — | — | US | disclosed |
| CN-1314899-A | Retinoid-associated receptor regulators | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 2001-09-26 | — | — | CN | disclosed |
| EP-1092711-A1 | RETINOID-ASSOCIATED RECEPTOR REGULATORS | Takeda Chemical Industries, Ltd. (JP) | 2001-04-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090253699-A1 | Compounds for Nonsense Suppression, and Methods for Their Use | NSUN2, UPF1, NSUN3 | NPC1 732/4885RAB9A 2618/4885SMN1; SMN2 104/4885 |
| US-20170204073-A1 | COMPOUNDS FOR NONSENSE SUPPRESSION, AND METHODS FOR THEIR USE | NSUN2, UPF1, NSUN3 | NPC1 732/4885RAB9A 2618/4885SMN1; SMN2 104/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.